David Ridley is the Faculty Director for Health Sector Management at Duke University’s Fuqua School of Business. He studies pharmaceutical innovation, manufacturing, and prices. He is especially interested in how to encourage development of drugs and vaccines for neglected diseases. David was the lead author of the paper proposing the priority review voucher program which became law and created a market of more than a billion dollars for drug development for neglected diseases. His research has been funded by the Bill & Melinda Gates Foundation and the National Institutes of Health. David teaches courses on health care policy and strategy to Duke University graduate students. He received a doctorate in economics from Duke University.
Liebman E, Lawler EC, Dunn A, Ridley DB. Consequences of a shortage and rationing: Evidence from a pediatric vaccine. Journal of health economics. 2023 Dec;92:102819.
Ridley DB, Ganapathy P, Kettler HE. US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug Development And Access. Health affairs (Project Hope). 2021 Aug;40(8):1243–51.
Ridley DB, Lee CY. Does medicare reimbursement drive up drug launch prices? Review of Economics and Statistics. 2020 Dec 1;102(5):980–93.